SCHEMBL4199338

SCHEMBL4199338

O=C(NCCO)c1cccc(-c2cncc(Nc3cccc(Cl)c3)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.57
XDH P47989 1/20 0.55
SLC22A12 Q96S37 1/20 0.55
CSNK2A2 P19784 4/20 0.53
CSNK2B P67870 4/20 0.53
CSNK2A1 P68400 4/20 0.53
CSNK2A3 Q8NEV1 4/20 0.53
CLK2 P49760 3/20 0.53
ALDH1A1 P00352 1/20 0.53
FYN P06241 2/20 0.52
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
EGFR P00533 3/20 0.48
FGFR2 P21802 2/20 0.48
GSK3A P49840 2/20 0.48
GSK3B P49841 2/20 0.48
INSR P06213 1/20 0.48
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180458 0.89 XDH (0.51) KDRXDHSLC22A12FYNBRAF
SCHEMBL4187667 0.87 L3MBTL1 (0.46) KDRXDHSLC22A12FYNEGFR
SCHEMBL4187560 0.84 SIRT2 (0.51) KDRALDH1A1FYNMEN1KMT2A
SCHEMBL4190144 0.84 ALDH1A1 (0.47) CSNK2A1ALDH1A1FYNMEN1KMT2A
SCHEMBL4191929 0.82 XDH (0.61) KDRXDHSLC22A12CSNK2A2CSNK2B
SCHEMBL4183159 0.81 FYN (0.55) XDHSLC22A12ALDH1A1FYNMEN1
SCHEMBL4199241 0.78 KDR (0.55) KDRXDHSLC22A12CSNK2A2CSNK2B
SCHEMBL6510118 0.77 ABL1 (0.63) CSNK2A2CSNK2BCSNK2A1CSNK2A3CLK2
SCHEMBL4191746 0.76 BRAF (0.68) KDRXDHSLC22A12FYNBRAF
SCHEMBL4188883 0.75 HDAC2 (0.50) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 KDR 4228/4885XDH 1630/4885SLC22A12 3973/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 KDR 4228/4885XDH 1630/4885SLC22A12 3973/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 KDR 4228/4885XDH 1630/4885SLC22A12 3973/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA KDR 3935/4885XDH 527/4885SLC22A12 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.